On June 22, 2026, three insiders at Enliven Therapeutics, Inc. (ELVN) collectively sold shares valued at approximately $107.15 million. Advisors Llc Orbimed, Capital Gp Vii Llc Orbimed, and Genesis Gp Llc Orbimed each sold 787,024 shares at a price of $45.38 per share, totaling $35.72 million for each entity.
These transactions represent a significant divestment by major shareholders. While insider selling can be attributed to various personal financial strategies, including diversification or tax planning, coordinated sales by multiple significant holders can draw market attention.
The aggregated sales amount to a substantial portion of the company's outstanding shares. Further monitoring of Enliven Therapeutics' stock performance and any subsequent filings may provide additional context to these insider transactions.